Management of Sodium Overcorrection During CRRT
If sodium is overcorrected in the first 24 hours on CRRT, immediately discontinue standard-sodium CRRT fluids and switch to low-sodium (119-126 mEq/L) dialysate and replacement fluids, while considering desmopressin administration to prevent osmotic demyelination syndrome.
Immediate Actions
Stop current CRRT fluids immediately if sodium correction exceeds 8 mmol/L in 24 hours (or 6 mmol/L in high-risk patients with DKA, renal impairment, or malnutrition) 1.
- Switch to low-sodium CRRT fluids (119-126 mEq/L dialysate and replacement fluids) to control the rate of further correction 2.
- Administer desmopressin 1-2 µg parenterally every 6-8 hours to induce water retention and slow sodium rise 3.
- Consider D5W infusion through a separate line to provide free water and help relower sodium if overcorrection is severe 1, 4.
Target Correction Rates Based on Risk Profile
Standard Risk Patients
- Maximum 8 mmol/L per 24 hours, not exceeding 10-12 mmol/L total 1.
High-Risk Patients (DKA, renal failure, malnutrition)
- Maximum 4-6 mmol/L per 24 hours, not exceeding 8 mmol/L total 1, 5.
- Patients with DKA are particularly vulnerable due to pre-existing osmotic shifts and require even more cautious correction 6, 5.
CRRT-Specific Management Strategy
Low-sodium CRRT fluids (119-126 mEq/L) provide controlled correction in severely hyponatremic patients, with mean sodium increases of only 3 mEq/L at 24 hours and 6 mEq/L at discontinuation 2.
- Initial CRRT effluent dose: 25-30 mL/kg/h using low-sodium fluids 2.
- Standard-sodium fluids (140 mEq/L) cause excessively rapid correction and should be avoided in patients with baseline sodium <126 mEq/L 2.
- Only 11% of patients using low-sodium CRRT fluids had sodium increases >6 mEq/L at 24 hours, with zero cases of osmotic demyelination syndrome 2.
Monitoring Protocol
Check serum sodium every 2 hours during the first 6-12 hours after intervention, then every 4 hours once correction rate is controlled 1.
- Monitor for osmotic demyelination syndrome signs: dysarthria, dysphagia, oculomotor dysfunction, quadriparesis (typically appearing 2-7 days post-overcorrection) 1.
- Track fluid balance meticulously with daily weights, input/output measurements, and hemodynamic monitoring 6, 4.
- Assess volume status frequently as CRRT can cause rapid fluid shifts 6.
Special Considerations for DKA Patients
DKA patients require corrected sodium calculations (add 1.6 mEq/L for each 100 mg/dL glucose >100 mg/dL) to assess true sodium status 6.
- Fluid replacement in DKA: Use 0.45% NaCl at 4-14 mL/kg/h if corrected sodium is normal/elevated; use 0.9% NaCl if corrected sodium is low 6.
- The induced change in serum osmolality must not exceed 3 mOsm/kg/h to prevent cerebral edema 6, 4.
- Concurrent potassium management is critical: Add 20-30 mEq/L potassium (2/3 KCl, 1/3 KPO4) once renal function assured 6, 4.
Calculating Reversal Strategy
If overcorrection has occurred, calculate how much to relower sodium using: Desired decrease in Na (mEq/L) × (0.5 × ideal body weight in kg) 1.
- D5W administration rate: Total volume needed ÷ desired correction time (typically 24-48 hours) 4.
- Target: Bring total 24-hour correction back to ≤8 mEq/L from starting point 1.
Common Pitfalls to Avoid
Never continue standard-sodium CRRT fluids in patients with baseline sodium <126 mEq/L, as this guarantees overcorrection 2.
- Do not delay intervention waiting for symptoms of osmotic demyelination—prevention is critical as treatment options are limited once it develops 1, 3.
- Avoid relying on clinical assessment alone for volume status in CRRT patients, as physical exam has poor sensitivity (41%) and specificity (80%) 1.
- Never correct faster thinking "the patient can tolerate it" in DKA with renal impairment—these patients have the highest risk for complications 1, 5.
Hypertonic Saline Precautions
If hypertonic saline was used, discontinue immediately upon recognizing overcorrection 7.
- Hypertonic saline carries risks of fluid overload, hypervolemia, pulmonary edema, and should be used with particular caution in patients with renal impairment, cirrhosis, or heart failure 7.
- Monitor for hypersensitivity reactions: tachycardia, chest pain, dyspnea, hypotension, which require immediate cessation 7.